Press Releases
DFINE STAR™ TUMOR ABLATION SYSTEM OFFERS RAPID PALLIATIVE TREATMENT OPTION FOR SARCOMA PATIENTS WITH RADIORESISTANT SPINE TUMORS
SAN JOSE, Calif.,June 5, 2013 -- DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced results presented this week at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.The presentation entitled “Targeted Radiofrequency Ablation™ (t-RFA) of Metastatic Posterior Vertebral Body Lesions in Patients With Soft Tissue Sarcomas,” highlighted successful treatment outcomes in radioresistant tumors using the DFINE STAR™ Tumor Ablation System
STUDIES AT AMERICAN SOCIETY OF NEURORADIOLOGY (ASNR) ANNUAL MEETING HIGHLIGHT BENEFITS OF DFINE StabiliT® VERTEBRAL AUGMENTATION SYSTEM FOR THE TREATMENT OF VERTEBRAL COMPRESSION FRACTURES (VCFs)
SAN JOSE, Calif. May 22, 2013 -- DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced results from three studies presented at The American Society of Neuroradiology (ASNR) Annual Meeting in San Diego.
STUDY DEMONSTRATES SIGNIFICANT PAIN REDUCTION WITH DFINE STAR™ TUMOR ABLATION SYSTEM IN SPINAL METASTASES
SAN JOSE, Calif. – May 1, 2013 – DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, released study results highlighting the clinical benefits of advanced Targeted-Radiofrequency Ablation™ (t-RFA) therapy for the management of patients experiencing painful spinal lesions. Eighty-five percent of patients with metastatic disease will develop spinal metastases – of these nearly 75 percent will involve the axial skeleton.
NEW STUDIES SHOW CLINICALLY SIGNIFICANT PALLIATION OF PAINFUL SPINAL METASTASES WITH DFINE STAR™ TUMOR ABLATION SYSTEM
SAN JOSE, Calif. – April 17, 2013 – DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, released results from two studies presented at the Society of Interventional Radiology’s Annual Scientific Meeting. Results from both studies underscore the benefits of advanced Targeted-Radiofrequency Ablation™ (t-RFA) therapy using the STAR™ Tumor Ablation System for the treatment of painful malignant lesions of the vertebral body.
GROWING BODY OF EVIDENCE SUPPORTS USE OF DFINE’S TARGETED RADIOFREQUENCY ABLATION™ (t-RFA) FOR TREATMENT OF SPINAL TUMORS
SAN JOSE, Calif. – Feb. 26, 2013 – DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today released data presented at the 2013 Annual Symposium of the American Society of Spine Radiology (ASSR) on Feb. 22, 2013. Results from the study reinforce earlier clinical reports of t-RFA using the STAR™ Tumor Ablation System for the treatment of malignant lesions of the spine.
DFINE ANNOUNCES LAUNCH OF StabiliT ® ERX, THE LATEST ADVANCEMENT IN FAMILY OF ENERGY-RESPONSIVE, ULTRA-HIGH VISCOSITY BONE CEMENTS
SAN JOSE, Calif. – Jan. 29, 2013 –DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced the launch of its StabiliT® ERX Bone Cement for use with the company’sStabiliT® Vertebral Augmentation System. The System harnesses the power of RadioFrequency Targeted Vertebral Augmentation™ (RF-TVA) to relieve pain and repair vertebral compression fractures (VCFs) resulting from instability due to osteoporosis or cancer.
PHYSICIANS REPORT SUCCESSFUL CLINICAL USE OF THE DFINE STAR™ TUMOR ABLATION SYSTEM IN MALIGNANT LESIONS OF THE SPINE
SAN JOSE, Calif. – Jan. 22, 2013 –DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced results of a multicenter clinical experience with Targeted Radiofrequency Ablation™ (t-RFA) therapy for malignant lesions of the spine using the DFINE STAR™ Tumor Ablation System. The STAR System enables physicians to provide patients with rapid pain relief from metastatic vertebral body spinal tumors in a single, minimally invasive treatment.
DFINE ANNOUNCES EXCLUSIVE DISTRIBUTION AGREEMENT WITH BIOMET
SAN JOSE, Calif. – Jan. 8, 2013 –DFINE, Inc., the developer of minimally invasive radiofrequency (RF)
targeted therapies for the treatment of vertebral pathologies, today announced it has entered into an exclusive distribution agreement with Biomet, Inc. for itsStabiliT® Vertebral Augmentation System in Spain and
Portugal.The term of the distribution agreement will be for three years.